A Phase 4 interventional study of Butterfly iQ3 ultrasound system for determination of postpartum volume status and Oral furosemide in Preeclampsia, Preeclampsia Postpartum and Preeclampsia Severe or Mild, sponsored by University of California, Irvine. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by University of California, Irvine · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Pre-Eclampsia with a site in United States — 62 open to participants now, 78 under way, 6 of them phase 3. Pre-Eclampsia · United States.
Among the 230 studies in Pre-Eclampsia with a site in United States, this one is the 76th largest by planned enrollment of the 161 interventional ones that give a count, is one of 27 that started in 2026, is one of 31 in phase 4, reaches primary completion later than 54 of the 77 other live ones, and was the 204th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →62 of the 230 studies in Pre-Eclampsia with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–50 · Women only
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
Texas Southern University · Sites in United States
Ages 18–45 · Women only
Medicines360 · Sites in United States
Ages 18–99 · Women only · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 24 · Phase 3 15 · Phase 4 31
First in 2000; this study’s year is marked. 27 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 89 across the 161 interventional studies, 125 across the 69 observational. Of the 126 that completed or were terminated, 54 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 230 have an industry lead sponsor. The 10 most frequent:
University of California, Irvine is the lead sponsor of 478 studies on the registry; 99 are open to participants now.
Of its 41 completed or terminated interventional studies of FDA-regulated products, 30 (73%) have results posted.
University of California, Irvine has 2 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
26 of the studies in Pre-Eclampsia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222852Phase 3Women and Infants Hospital of Rhode IslandCardiovascular Protection After Preeclampsia With Enalapril | 2027-10-15 |
| NCT07356518Wake Forest University Health SciencesTelehealth and Remote Blood Pressure | 2026-12 |
| NCT05676476University of Alabama at BirminghamThe ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy. | 2026-12 |
| NCT05924971MemorialCare Health SystemAspirin for Postpartum Patients With Preeclampsia | 2026-12 |
| NCT06523569Northwestern UniversityMobile Health Interventions to Prevent Heart Disease After Hypertensive Disorders of Pregnancy | 2026-12-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 230 studies in Pre-Eclampsia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study explores a novel approach to improving care for postpartum patients with preeclampsia, a pregnancy-related condition characterized by high blood pressure, protein in the urine, and organ dysfunction. Preeclampsia affects up to 9% of pregnancies and can progress to include complications of seizures, stroke, and even death. Over 60% of patients with preeclampsia continue to experience high blood pressure at the time of discharge from their delivery hospitalization, and many of these patients require blood pressure medications for up to 6 months postpartum. Even with blood pressure medications, many of these patients are readmitted to the hospital within six weeks of delivery.
In this study, the investigators will utilize point-of-care ultrasound (POCUS), a quick and non-invasive, bedside imaging strategy, to look for signs of excess fluid accumulating in the lungs and venous system of postpartum patients with preeclampsia. Because excess fluid has the potential to worsen blood pressure, subjects with evidence of this on POCUS would be treated with a diuretic medication called furosemide (either orally or intravenously) within 24 hours of delivery.
The investigators' main goal is to determine whether using POCUS can help physicians make better treatment decisions and improve short-term outcomes for postpartum patients with preeclampsia. The investigators' aim to achieve faster recovery of blood pressure, reduce the need for blood pressure medication at hospital discharge, and lower the rates of hospital readmission for those with preeclampsia. This study could significantly enhance the overall care and health of postpartum patients.
Preeclampsia is a condition of the antenatal and postpartum periods, which manifests as new-onset hypertension and proteinuria. Globally, preeclampsia is estimated to affect up to 9% of all pregnancies, though as many as 63% of patients who receive this diagnosis will remain hypertensive beyond the time of postpartum hospital discharge. Because of this, up to 36% of patients with preeclampsia will require antihypertensive therapy at the time of hospital discharge, and between 26 - 74% of patients with preeclampsia will be readmitted during the first six weeks' postpartum. Cumulatively, these preeclampsia-related outcomes result in United States medical expenditures exceeding $36 million annually.
One proposed strategy for improving outcomes among patients with preeclampsia is postpartum administration of diuretics. This treatment is posited to target preeclampsia-related volume overload, which in turn is thought to contribute to continued hypertension in the postpartum period. The earliest trial on the use of diuretics for this purpose was published by Ascarelli et al in 2005 and involved randomization of 264 postpartum patients with preeclampsia to either a 5-day course of oral furosemide 20mg daily or standard preeclampsia management. Outcomes from this study included blood pressure changes over the postpartum hospital stay, need for antihypertensive therapy during hospitalization and at discharge, length of postpartum hospital stay, and other postpartum complications. While this intervention lowered systolic blood pressure by over 10 mm Hg in the first 48 hours postpartum, it did not result in a statistically significant decrease in antihypertensive therapy requirements, postpartum length of stay, or the frequency of other postpartum complications. As recently as 2021, Perdigao and colleagues published the FoR BP trial, which similarly randomized 384 postpartum patients with hypertensive disorders of pregnancy to either a 5-day course of oral furosemide 20mg daily or standard preeclampsia management. Primary outcomes from this study were slightly different from the Ascarelli et al study and included persistent hypertension 7 days postpartum and days to resolution of hypertension. Ultimately, Perdigao et al's results were more promising and demonstrated that a brief course of oral diuretics reduced the incidence of persistent hypertension by nearly 60% in patients with hypertensive disorders of pregnancy.
A potential explanation for this discrepancy in findings from earlier studies is that volume overload affects only a subset of patients with preeclampsia. While preeclamptic patients with volume overload are likely to demonstrate a meaningful response to diuresis, those without significant volume overload are less likely to respond to this treatment. Because the aforementioned studies did not account for patients' volume status at the time of randomization or diuretic administration, it seems possible that they did not sufficiently capture the patient population most likely to respond to the intervention of interest.
With regards to evaluating postpartum volume status and how it might relate to diuretic response, most obstetric practitioners currently rely on findings from physical examination (e.g. jugular venous distension, rales on lung exam, peripheral edema) that are known to have limited sensitivity. However, there is increasing evidence in the obstetric literature that use of POCUS might be a helpful adjunct for determining postpartum volume status. In 2023, Chong et al conducted a prospective cohort study of 31 patients who experienced at least 500mL blood loss during vaginal delivery. These investigators used POCUS to assess the IVC collapsibility index during the first, second, and third stages of labor as well as at the time of bleeding and following rapid resuscitation with 500mL of intravenous fluids. Chong and investigators then compared these indices to heart rate and mean arterial pressure at the same intervals and found that the IVC collapsibility index demonstrated more variation in response to volume status than did either heart rate or mean arterial pressure, both of which instead remained relatively stable over time. Moreover, a review of POCUS' role in monitoring the response to postpartum volume resuscitation was published in the American Journal of Obstetrics \& Gynecology in 2024. This review suggested that the presence of three or more B-lines per screen on lung ultrasound is indicative of pulmonary edema during pregnancy and the postpartum period, as B-lines develop when air content in the lungs is replaced by transudate or exudate in the interstitium. It further suggested that an enlarged IVC diameter (> 2.0 cm) or minimal IVC collapsibility index (\<15%) identified on POCUS could also be used to determine volume overload antenatally and postnatally.
The purpose of this study is to determine whether point-of-care ultrasound (POCUS) assessment of the lungs and inferior vena cava (IVC), both of which are a proxy for volume status, can be used to guide postpartum diuretic therapy in individuals with preeclampsia, and whether this strategy improves short-term maternal outcomes for this high-risk patient population.
The central study hypothesis is that, when guided by POCUS, use of diuretic therapy will improve postpartum outcomes in patients with preeclampsia relative to standard postpartum management alone. The investigators will test this hypothesis by conducting a pilot prospective cohort study that addresses the following aims:
Specific Aim 1: Assess the feasibility of POCUS assessment of the lungs and IVC in postpartum patients with preeclampsia within 24 hours of delivery.
To date, only a small handful of studies has evaluated the role of POCUS in patients with preeclampsia, the most recent of which was presented at the Society for Maternal-Fetal Medicine's Annual Pregnancy Meeting in February of this year. This pilot study conducted at the University of Tennessee Health Science Center compared the median IVC collapsibility index in 12 participants with preeclampsia with severe features to that in 10 participants without hypertensive disorders of pregnancy. Although the researchers found no significant difference in median IVC collapsibility index between the study groups, the results suggest that POCUS assessment of the IVC is at least feasible in a newly postpartum patient.
Thus, with respect to this specific aim, the investigators hypothesize that POCUS assessment will be able to successfully determine volume status in postpartum patients with preeclampsia. Specifically, the investigators anticipate that POCUS can be reliably used to identify the presence of B-lines in the lungs and to measure the greatest IVC diameter and IVC collapsibility index.
Specific Aim 2: Determine whether use of POCUS assessment to guide diuretic administration improves postpartum outcomes, including persistent hypertension at hospital discharge, time to normotension, antihypertensive use at hospital discharge, and hospital readmission, among patients with preeclampsia.
With respect to this specific aim, the investigators hypothesize that if oral or intravenous furosemide is administered to postpartum patients with preeclampsia following POCUS assessment that identifies 3 or more B-lines, an IVC diameter above 2cm, and/or an IVC collapsibility index less than 15%, there will be a decrease in persistent hypertension at hospital discharge (\< 140/90 mm Hg and \< 130/80 mm Hg), time to normotension, antihypertensive use at hospital discharge, and hospital readmission.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Historical cohort (group 1):
Prospective cohorts (groups 2 and 3):
Exclusion Criteria:
Historical cohort (group 1):
Prospective cohorts (groups 2 and 3):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A prospective cohort of patients diagnosed with preeclampsia who will be enrolled and undergo POCUS within 24 hours of delivery. Those meeting pre-specified hemodynamic criteria (\> 3 B-lines, maximum IVC diameter \> 2 cm, and/or IVC collapsibility index \< 15%) will receive a 5-day course of oral furosemide 20mg and oral potassium chloride 40mEq daily.
Diagnostic Test: Butterfly iQ3 ultrasound system for determination of postpartum volume status · Drug: Oral furosemide
A prospective cohort of patients diagnosed with preeclampsia who will be enrolled and undergo POCUS within 24 hours of delivery. Those meeting pre-specified hemodynamic criteria (\> 3 B-lines, maximum IVC diameter \> 2 cm, and/or IVC collapsibility index \< 15%) will receive a single dose of intravenous furosemide 40mg and oral potassium chloride 40mEq.
Diagnostic Test: Butterfly iQ3 ultrasound system for determination of postpartum volume status · Drug: Intravenous furosemide
A retrospective cohort comprised of patients who delivered before implementation of POCUS-guided postpartum management of preeclampsia (1/1/2024 - 6/1/2025). These patients will be selected from the electronic medical record and matched to enrolled patients for variables such as age, body mass index, gestational age at delivery, severity of preeclampsia, and mode of delivery.
Drug: Oral furosemide · Drug: Intravenous furosemide
A trained study staff member will perform point-of-care ultrasound (POCUS) of the lungs and the inferior vena cava (IVC). All POCUS assessments will be performed using either the curvilinear or phased array settings on a portable Butterfly iQ3 ultrasound system. Images obtained via the Butterfly iQ3 ultrasound system will be labeled according to the subject's unique identification number and transmitted directly to a digital study archive. The lead investigator or physician of record will review all captured ultrasound images to ensure that an appropriate therapy is selected moving forward. Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider.
Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider. The first cohort of 48 patients will be treated with oral furosemide 20mg daily and oral potassium chloride 40mEq daily for a total of 5-days. As patients delivered vaginally are typically discharged 2-3 days after birth and delivered via cesarean are typically discharged 4-5 days after birth, patients who have not yet completed the medication course by the time of planned discharge will be prescribed the remainder of their medications before departing the hospital.
Also known as: Oral Lasix
Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider. The second cohort of 48 patients will be treated with a single dose of intravenous furosemide 40mg and oral potassium chloride 40mEq on postpartum day 1.
Also known as: Intravenous Lasix
Proportion of subjects with persistent hypertension at time of postpartum hospital discharge
Persistent hypertension at time of postpartum hospital discharge, defined both as blood pressure \> 140/90 mm Hg according to American College of OB/GYN (ACOG) guidelines and 130/80 mm Hg according to Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-9) guidelines
Time frame: From study enrollment through completion of study participation, an average of 7 days or less
Average days to resolution of hypertension
Days to resolution of hypertension, defined both as blood pressure \< 140/90 mm Hg according to ACOG guidelines and 130/80 mm Hg according to JNC-9 guidelines
Time frame: From study enrollment through completion of study participation, an average of 7 days or less
Proportion of subjects requiring antihypertensive medications at hospital discharge
Need for antihypertensive medication at postpartum hospital discharge
Time frame: From study enrollment through completion of study participation, an average of 7 days or less
Proportion of subjects requiring a secondary antihypertensive therapy at hospital discharge
Addition of second antihypertensive agent during postpartum hospitalization
Time frame: From study enrollment through completion of study participation, an average of 7 days or less
Average length of hospital stay
Length of postpartum hospitalization
Time frame: From birth through completion of study participation, an average of 7 days or less
Proportion of patients with a change in POCUS results over time
Change in POCUS results from positive to negative for evidence of volume overload from the time of study enrollment through hospital discharge
Time frame: From study enrollment through completion of study participation, an average of 7 days or less
Mean change in BNP levels over time
Change in brain natriuretic peptide (BNP) levels from the time of study enrollment through hospital discharge
Time frame: From study enrollment through completion of study participation, an average of 7 days or less
Proportion of patients with hospital readmission for high blood pressure
Readmission for blood pressure control within 30 days of discharge from initial postpartum hospitalization
Time frame: From time of initial hospital discharge through 30 days postpartum
Feasibility for future study
Feasibility for future study, defined both as the number of subjects enrolled divided by the number of subjects with acceptable POCUS lung or IVC ultrasound images collected within 24 hours of delivery and as reliability between image assessment as performed by study staff and by blind reviewer
Time frame: From study enrollment through completion of study participation, an average of 7 days or less
Proportion of patients with hypotension
Hypotension, defined as blood pressure \< 90 mm Hg systolic and/or \< 60 mm Hg diastolic
Time frame: From study enrollment through completion of study participation, an average of 7 days or less
Proportion of patients with tachycardia
Tachycardia, defined as heart rate \> 100 beats per minute
Time frame: From study enrollment through completion of study participation, an average of 7 days or less
Proportion of patients with moderate or severe hypokalemia
Moderate or severe hypokalemia, defined as potassium \< 3.0 mEq/L
Time frame: From study enrollment through completion of study participation, an average of 7 days or less
Proportion of patients with acute kidney injury
Acute kidney injury, defined as creatinine \> 1.1 mg/dL
Time frame: From study enrollment through completion of study participation, an average of 7 days or less
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Start is estimated for Oct 2026; primary completion for Jun 2028, 19 months later.
Of 35 phase 4 interventional studies under Pre-Eclampsia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's planned 19 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Furosemide
University of California, Irvine →